Evommune, Inc. (NYSE: EVMN) presented late-breaking Phase 2a proof-of-concept data for its drug candidate EVO301 in adults with moderate-to-severe atopic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE